( ARTG ) PADCEV, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC).,PADCEV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed dea

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-

OTC

PADCEV powder for concentrate for solution for infusion 20 mg

INN: ENFORTUMAB VEDOTIN

Data updated: 2026-04-24

Available in:

🇨🇿🇬🇧🇵🇹🇸🇰

Form

—

Dosage

—

Route

—

Storage

—

About This Product

ATC Code

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.